Skip to Content

AbbVie Inc ABBV Stock Quote

| Rating as of


Morningstar‘s AbbVie Stock Analysis ABBV

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


AbbVie Posts Solid Q3, but Uncertain Outlook for Humira Likely Weighing on the Stock

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

AbbVie reported third-quarter results slightly above our projections, but we don’t expect any major changes to our fair value estimate on the minor outperformance. We continue to view the stock as slightly overvalued with the market not fully appreciating the U.S. biosimilar Humira pressure likely starting in 2023. Nevertheless, we remain confident in AbbVie’s narrow moat due to the strong entrenchment of several newer drugs, especially immunology drugs Skyrizi and Rinvoq.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ABBV

Company Profile ABBV

Business Description

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

1 North Waukegan Road
North Chicago, IL, 60064-6400
T +1 847 932-7900
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 50,000

Related News ABBV